Poly-Lysine Dendritic Nanocarrier to Target Epidermal Growth Factor Receptor Overexpressed Breast Cancer for Methotrexate Delivery
A fourth generation poly-lysine dendritic nanocarrier (P<sub>4</sub>LDN)-based targeted chemotherapy for breast cancer is attempted by incorporating an epidermal growth factor receptor (EGFR)-specific short peptide E2 (ARSHVGYTGAR) and the drug methotrexate (MTX) into a nanocarrier syste...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-01-01
|
| Series: | Materials |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1996-1944/15/3/800 |
| _version_ | 1797486724618649600 |
|---|---|
| author | Pratibha Narayanan Anju Krishnan Anitha Neethu Ajayakumar Kesavakurup Santhosh Kumar |
| author_facet | Pratibha Narayanan Anju Krishnan Anitha Neethu Ajayakumar Kesavakurup Santhosh Kumar |
| author_sort | Pratibha Narayanan |
| collection | DOAJ |
| description | A fourth generation poly-lysine dendritic nanocarrier (P<sub>4</sub>LDN)-based targeted chemotherapy for breast cancer is attempted by incorporating an epidermal growth factor receptor (EGFR)-specific short peptide E2 (ARSHVGYTGAR) and the drug methotrexate (MTX) into a nanocarrier system. The drug is incorporated into the nanocarrier using a cathepsin B cleavable spacer: glycine–phenylalanine–leucine–glycine (GFLG). The in vitro analysis of the time-dependent drug release, binding and internalization ability, and the cytotoxic nature showed that this drug delivery system (DDS) is highly effective. The efficacy analysis using non-obese diabetic/severe combined immunodeficiency (NOD-SCID) mice also showed that compared to the control group, the DDS can effectively reduce tumor volume. The mice that received the DDS appeared to gain weight more rapidly than the free drug, which suggests that the dendrimer is more easily tolerated by mice than the free drug. |
| first_indexed | 2024-03-09T23:38:21Z |
| format | Article |
| id | doaj.art-c796a2063b03495896a48f77d1caf43f |
| institution | Directory Open Access Journal |
| issn | 1996-1944 |
| language | English |
| last_indexed | 2024-03-09T23:38:21Z |
| publishDate | 2022-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Materials |
| spelling | doaj.art-c796a2063b03495896a48f77d1caf43f2023-11-23T16:57:21ZengMDPI AGMaterials1996-19442022-01-0115380010.3390/ma15030800Poly-Lysine Dendritic Nanocarrier to Target Epidermal Growth Factor Receptor Overexpressed Breast Cancer for Methotrexate DeliveryPratibha Narayanan0Anju Krishnan Anitha1Neethu Ajayakumar2Kesavakurup Santhosh Kumar3Pathogen Biology Division, Rajiv Gandhi Centre for Biotechnology, Bio-Innovation Centre, KINFRA Park, Chanthavila (PO), Thiruvananthapuram 695585, Kerala, IndiaPathogen Biology Division, Rajiv Gandhi Centre for Biotechnology, Bio-Innovation Centre, KINFRA Park, Chanthavila (PO), Thiruvananthapuram 695585, Kerala, IndiaPathogen Biology Division, Rajiv Gandhi Centre for Biotechnology, Bio-Innovation Centre, KINFRA Park, Chanthavila (PO), Thiruvananthapuram 695585, Kerala, IndiaPathogen Biology Division, Rajiv Gandhi Centre for Biotechnology, Bio-Innovation Centre, KINFRA Park, Chanthavila (PO), Thiruvananthapuram 695585, Kerala, IndiaA fourth generation poly-lysine dendritic nanocarrier (P<sub>4</sub>LDN)-based targeted chemotherapy for breast cancer is attempted by incorporating an epidermal growth factor receptor (EGFR)-specific short peptide E2 (ARSHVGYTGAR) and the drug methotrexate (MTX) into a nanocarrier system. The drug is incorporated into the nanocarrier using a cathepsin B cleavable spacer: glycine–phenylalanine–leucine–glycine (GFLG). The in vitro analysis of the time-dependent drug release, binding and internalization ability, and the cytotoxic nature showed that this drug delivery system (DDS) is highly effective. The efficacy analysis using non-obese diabetic/severe combined immunodeficiency (NOD-SCID) mice also showed that compared to the control group, the DDS can effectively reduce tumor volume. The mice that received the DDS appeared to gain weight more rapidly than the free drug, which suggests that the dendrimer is more easily tolerated by mice than the free drug.https://www.mdpi.com/1996-1944/15/3/800poly-lysine dendritic nanocarriertargeted drug deliverybreast cancermethotrexateepidermal growth factor receptorin silico approach |
| spellingShingle | Pratibha Narayanan Anju Krishnan Anitha Neethu Ajayakumar Kesavakurup Santhosh Kumar Poly-Lysine Dendritic Nanocarrier to Target Epidermal Growth Factor Receptor Overexpressed Breast Cancer for Methotrexate Delivery Materials poly-lysine dendritic nanocarrier targeted drug delivery breast cancer methotrexate epidermal growth factor receptor in silico approach |
| title | Poly-Lysine Dendritic Nanocarrier to Target Epidermal Growth Factor Receptor Overexpressed Breast Cancer for Methotrexate Delivery |
| title_full | Poly-Lysine Dendritic Nanocarrier to Target Epidermal Growth Factor Receptor Overexpressed Breast Cancer for Methotrexate Delivery |
| title_fullStr | Poly-Lysine Dendritic Nanocarrier to Target Epidermal Growth Factor Receptor Overexpressed Breast Cancer for Methotrexate Delivery |
| title_full_unstemmed | Poly-Lysine Dendritic Nanocarrier to Target Epidermal Growth Factor Receptor Overexpressed Breast Cancer for Methotrexate Delivery |
| title_short | Poly-Lysine Dendritic Nanocarrier to Target Epidermal Growth Factor Receptor Overexpressed Breast Cancer for Methotrexate Delivery |
| title_sort | poly lysine dendritic nanocarrier to target epidermal growth factor receptor overexpressed breast cancer for methotrexate delivery |
| topic | poly-lysine dendritic nanocarrier targeted drug delivery breast cancer methotrexate epidermal growth factor receptor in silico approach |
| url | https://www.mdpi.com/1996-1944/15/3/800 |
| work_keys_str_mv | AT pratibhanarayanan polylysinedendriticnanocarriertotargetepidermalgrowthfactorreceptoroverexpressedbreastcancerformethotrexatedelivery AT anjukrishnananitha polylysinedendriticnanocarriertotargetepidermalgrowthfactorreceptoroverexpressedbreastcancerformethotrexatedelivery AT neethuajayakumar polylysinedendriticnanocarriertotargetepidermalgrowthfactorreceptoroverexpressedbreastcancerformethotrexatedelivery AT kesavakurupsanthoshkumar polylysinedendriticnanocarriertotargetepidermalgrowthfactorreceptoroverexpressedbreastcancerformethotrexatedelivery |